Mannitol for Prevention of AKI After Liver Transplantation Mannitol for Prevention of AKI After Liver Transplantation
Acute kidney injury is a common complication after liver transplantation. Might mannitol, an oxygen free radical scavenger, reduce the risk?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 2, 2023 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Unvaccinated Kidney And Heart Patients Denied Transplants Get Day In Court With Michigan Hospital
Authored by Steven Kovac via The Epoch Times (emphasis ours), A group of activists join Ross Barranco to protest COVID-19 vaccination mandates in Rochester Hills, Mich. on Dec. 21, 2021. (Courtesy of…#getdayincourt #michiganhospital #stevenkovac #epochtimes #rossbarranco #rochesterhills #mich #michigan #barranco #deborahcatalono (Source: Reuters: Health)
Source: Reuters: Health - January 31, 2023 Category: Consumer Health News Source Type: news

Janssen Announces Unblinding of Phase 3 CARTITUDE-4 Study of CARVYKTI ® (cilta-cel) as Primary Endpoint Met in Treatment of Patients with Relapsed and Refractory Multiple Myeloma
RARITAN, New Jersey, January 27, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) versus pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide, and dexamethasone (DPd) for the treatment of patients with relapsed and lenalidomide-refractory multiple myeloma met its primary endpoint of significant improvement in progression-free survival (PFS) at the first pre-specified interim analysis. As a result of meeting the primary endpoint, the Independent Data Monitoring Commi...
Source: Johnson and Johnson - January 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Genetic Analysis of Blood Type May Increase Number of Kidney Transplant Matches
Using genetics to more accurately identify individuals with a subtype of A blood could result in over 1,000 more kidney transplants to type B individuals, improving availability as well as equity in kidney transplantation (Source: BWH News)
Source: BWH News - January 18, 2023 Category: Hospital Management Source Type: news

Diabetics to get 'artificial pancreas' to end worry over finger-prick tests
More than 100,000 people with type 1 diabetes will be offered 'artificial pancreas' technology - which could help end the misery of amputations, kidney problems and blindness. (Source: Daily Express - Health)
Source: Daily Express - Health - January 10, 2023 Category: Consumer Health News Source Type: news

Opioid Prescribing Practices in Chronic Kidney Disease Opioid Prescribing Practices in Chronic Kidney Disease
A new study looks at opioid prescribing patterns for pain management in patients with chronic kidney disease. Are these drugs being prescribed appropriately?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 29, 2022 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Deferring CT premedication reduces patients' ED length of stay
Deferring steroid premedication in patients with noted iodinated contrast allergie...Read more on AuntMinnie.comRelated Reading: Does contrast-enhanced CT boost kids' acute kidney injury risk? Radiomic features on CT help classify ovarian cancer subtypes Photon-counting CT bests DSCT for reducing abdominal radiation dose Photon-counting CT proves value in driving down imaging dose CT radiomics helps predict HCC recurrence after liver transplant (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 23, 2022 Category: Radiology Source Type: news

Donor Kidney Transplants From SARS-CoV-2 Positive Donors Donor Kidney Transplants From SARS-CoV-2 Positive Donors
Could SARS-CoV-2 positive donor kidneys be safely considered for transplant? An assessment of post-transplant outcomes provides some insight.American Journal of Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 22, 2022 Category: Consumer Health News Tags: Transplantation Journal Article Source Type: news

Penn Medicine establishes Center for Living Donation to boost kidney, liver transplants
The center comes just two months after Penn Medicine teamed with Philadelphia-based Gift of Life Donor Program to establish the state's first medical unit exclusively for deceased organ and tissue donors. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 20, 2022 Category: Pharmaceuticals Authors: John George Source Type: news

Using Single-Cell Functional Analysis to Identify Cellular Drivers of Pathology
How single-cell secretomic analysis revealed the role of TEMRA CD8+ T cells in kidney transplant rejection. (Source: The Scientist)
Source: The Scientist - December 15, 2022 Category: Science Tags: The Marketplace Source Type: news

Janssen Presents Efficacy and Subgroup Analyses from MAIA Study Showing Long-Term Results of DARZALEX ® (daratumumab)-based Regimen in Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new analyses from the Phase 3 MAIA study of DARZALEX® (daratumumab) in combination with lenalidomide and dexamethasone (D-Rd), evaluating progression-free survival (PFS), minimal residual disease (MRD) negativity and overall response rate (ORR) at a median follow-up of 64.5 months, and overall survival (OS) at a median follow-up of 73.6 months in newly diagnosed, transplant-ineligible (TIE) patients with multiple myeloma, regardless of patients’ age and across clinically important subgroups, as well as health...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Ghana: From Deadline to Health Line ... the Story of a Kidney Failure Survivor
[Ghanaian Times] Dialysis, kid-ney transplant, or your life ends in the next five years," said the Doctor. That was the dilemma that Ms Abigail Ashley found herself in when she was diagnosed with chronic kidney disease (CKD) end-stage sometime in August 2007. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 12, 2022 Category: African Health Source Type: news

Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI ™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™ (teclistamab-cqyv), a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and lenalidomide. According to the results, the immune-based triplet therapy regimen had a manageable safety profile with no unexpected safety signals observed. A very good partial response (VGPR) or better was achieved by 90.3 percent of patients with relapsed or refractory multiple ...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

Nigeria: Medical Expert Begs FG to Subsidise Cost of Kidney Transplant
[Vanguard] Worried by the rising cost of a kidney transplant, a Consultant Nephrologist and the immediate-past chairman of the Nigeria Medical Association, NMA, Abia State, Dr Chimezie Okwuonu, has appealed to Government and corporate organizations to subsidize the cost of kidney transplant in Nigeria. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 10, 2022 Category: African Health Source Type: news

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news